Related Party Transactions (Details Narrative) (Supera Pharmaceuticals, Inc.) - Supera Pharmaceuticals, Inc. [Member] - USD ($) |
1 Months Ended | 12 Months Ended | |
|---|---|---|---|
Nov. 30, 2018 |
Dec. 31, 2020 |
Dec. 31, 2019 |
|
| Line of credit expiration date | Dec. 31, 2022 | ||
| Line of credit facility, interest rate | 5.00% | ||
| Shareholder [Member] | |||
| Line of credit facility, maximum borrowing capacity | $ 1,000,000 | ||
| Related Party [Member] | |||
| Lease costs | $ 600,000 | $ 600,000 | |
| Accounts Payable, Trade | $ 477,000 | ||
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of lease cost recognized by lessee for lease contract. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Date the credit facility terminates, in CCYY-MM-DD format. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The effective interest rate during the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|